INTRODUCTION {#s1}
============

Cancer represents an enormous economic burden on society in both developing and developed countries. Based on the GLOBOCAN 2012 estimates, there were about 14.1 million new cancer cases in 2012, and 8.2 million deaths \[[@R1]\]. Cancer is a complex multifaceted disease that results from gene-environment interactions. Apart from the lifestyles associated with an increased risk of a number of common cancers, genetic variations, including single nucleotide polymorphism (SNP), have been known to affect cancer susceptibility.

Fibroblast growth factor receptors (FGFRs), composed of four related proteins (FGFR1-4), belong to the receptor tyrosine kinase (RTK) family. To date, more than 18 FGF ligands have been identified \[[@R2]\]. The binding of ligands to FGFRs triggers several downstream signal transduction cascades that are activated in cancer, including phospholipase C (PLC), phosphatidylinositol 3-kinase (PI3K), signal transducer and activator of transcription (STAT), as well as mitogen-activated protein kinases (MAPKs) \[[@R3], [@R4]\]. FGFRs participate in the regulation of multiple crucial biological activities, including cell proliferation and differentiation, migration, angiogenesis, and survival \[[@R3], [@R5], [@R6]\]. Numerous studies have indicated an aberrant FGFR signaling in carcinogenesis \[[@R2], [@R7], [@R8]\]. Recently, a large scale analysis of 4,853 solid tumors has revealed that 7.1% of cancers harbor FGFR aberrations, including gene amplifications (66%), mutations (26%), and rearrangements (8%) \[[@R9]\]. Over the past decade, different types of FGFR inhibitors have been developed to treat cancer, including multi-target tyrosine kinase inhibitors, FGFR specific tyrosine kinase inhibitors (TKIs), monoclonal antibodies, and FGF ligand traps \[[@R2], [@R10]\].

FGFR4 is a highly versatile protein that has more than 20 known ligands \[[@R5]\], and is highly expressed in various types of cancer \[[@R11]--[@R16]\]. Overexpression of FGFR4, but not other FGFRs, stimulates membrane ruffling, resulting in increased motility of COS-7 cells \[[@R17]\]. The *FGFR4* gene is highly polymorphic. A common nonsynonymous SNP rs351855, which causes a substitution of arginine instead of glycine in the transmembrane domain of the EGFR4 receptor (Gly388Arg) has been implicated in cancer development \[[@R18]\]. *FGFR4* gene rs351855 G\>A polymorphism has been associated with genetic predisposition to several types of cancer, including breast cancer \[[@R18]--[@R22]\], prostate cancer \[[@R23]--[@R26]\], head and neck cancer \[[@R27]\], lung cancer \[[@R28], [@R29]\], and hepatocellular carcinoma \[[@R13], [@R30], [@R31]\]. Unfortunately, the association between the *FGFR4* gene rs351855 G\>A polymorphism and cancer risk remains controversial. To systematically analyze the association between the *FGFR4* gene rs351855 G\>A polymorphism and cancer risk, we have performed this meta-analysis using 27 studies consisting of 8,682 cases and 9,731 controls.

RESULTS {#s2}
=======

Literature search {#s2_1}
-----------------

We have initially analyzed 115 potentially relevant publications. After full review, 91 articles were excluded for the following reasons: 1) they were review articles or meta-analyses, 2) they did not investigate association between the *FGFR4* rs351855 G\>A polymorphism and cancer risk, 3) they were not case-control studies, or 4) had no enough data reported to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). One article was further excluded because of the departure from Hardy--Weinberg equilibrium (HWE) \[[@R32]\]. Only 23 articles consisting of 27 individual studies investigated the association between the *FGFR4* rs351855 G\>A polymorphism and cancer risk, and fit the eligibility criteria (Figure [1](#F1){ref-type="fig"}).

![Flowchart of included studies](oncotarget-08-25300-g001){#F1}

In total, data were obtained on 18,413 subjects (8,682 cases and 9,731 controls) from 27 studies (Table [1](#T1){ref-type="table"}). The *FGFR4* rs351855 G\>A polymorphism was most often studied in breast cancer (6 studies) \[[@R18]--[@R22]\] and prostate cancer (6 studies) \[[@R23]--[@R26]\]. Other commonly investigated tumor types were colorectal cancer (CRC, 3 studies) \[[@R18], [@R20], [@R33]\], hepatocellular carcinoma (HCC, 3 studies) \[[@R13], [@R30], [@R31]\], and lung cancer (2 studies) \[[@R28], [@R29]\]. Additionally, studies on head and neck squamous cell carcinoma (HNSCC) \[[@R27]\], oral squamous cell carcinoma (OSCC) \[[@R34]\], non-Hodgkin lymphoma (NHL) \[[@R35]\], gastric cancer \[[@R36]\], skin cancer \[[@R37]\], glioblastoma \[[@R38]\], and sarcoma \[[@R39]\] were combined and categorized as "others" cancer type, since only one study for each tumor type was reported. Fourteen studies utilized population-based (PB) controls and ten had hospital-based (HB) controls. Source of control was not determined (ND) in three studies. Studies were most frequently conducted among Caucasians (14 studies), followed by Asians (11 studies), and Africans (2 studies). Eleven studies were considered as low quality (quality score ≤ 9), and 16 studies (56%) were considered as high quality studies (quality score \> 9).

###### Characteristics of studies included in the current meta-analysis

  Surname      Year   Cancertype   Country     Ethnicity   Design   Genotypemethod   Case   Control   MAF     HWE    Score                                        
  ------------ ------ ------------ ----------- ----------- -------- ---------------- ------ --------- ------- ------ ------- ----- -------- ------ ------ ------- ----
  Bange        2002   Breast       Russia      Caucasian   PB       PCR-RFLP         26     28        7       61     55      60    8        123    0.31   0.114   7
  Bange        2002   Breast       Germany     Caucasian   PB       PCR-RFLP         41     34        9       84     55      60    8        123    0.31   0.114   8
  Bange        2002   CRC          Italy       Caucasian   PB       PCR-RFLP         37     38        7       82     55      60    8        123    0.31   0.114   8
  Morimoto     2003   Sarcomas     Japan       Asian       NA       PCR-RFLP         54     72        17      143    39      50    13       102    0.37   0.624   6
  Wang         2004   Prostate     USA         Caucasian   PB       PCR-RFLP         125    117       42      284    53      40    4        97     0.25   0.291   7
  Wang         2004   Prostate     USA         African     PB       PCR-RFLP         37     6         2       45     76      18    0        94     0.10   0.305   6
  Spinola      2005   Lung         Italy       Caucasian   HB       Pyrosequencing   148    103       23      274    193     168   40       401    0.31   0.699   11
  Spinola      2005   Breast       Italy       Caucasian   HB       Pyrosequencing   67     55        20      142    112     83    25       220    0.30   0.117   10
  Spinola      2005   CRC          Italy       Caucasian   HB       Pyrosequencing   98     63        18      179    112     83    25       220    0.30   0.117   10
  Mawrin       2006   Glioma       Germany     Caucasian   HB       PCR-RFLP         39     51        4       94     10      13    2        25     0.34   0.428   10
  Ma           2008   Prostate     Japan       Asian       HB       PCR-RFLP         163    196       133     492    67      87    25       179    0.38   0.701   10
  Ansell       2009   HNSCC        Sweden      Caucasian   PB       PCR-RFLP         61               49^a^   110    81            111^a^   192    /      /       10
  FitzGerald   2009   Prostate     USA         Caucasian   PB       SNPlex           587    544       123     1254   631     496   124      1251   0.30   0.070   15
  FitzGerald   2009   Prostate     USA         African     PB       SNPlex           104    39        3       146    60      18    2        80     0.14   0.646   13
  Ho           2009   HCC          Singapore   Asian       PB       Sequencing       27     17        14      58     30      38    20       88     0.44   0.241   8
  Naidu        2009   Breast       Malaysia    Asian       HB       PCR-RFLP         179    172       36      387    132     105   15       252    0.27   0.322   9
  Nan          2009   Skin         USA         Caucasian   PB       Taqman           365    325       78      768    406     343   84       833    0.31   0.359   12
  Ho           2010   Prostate     UK          Caucasian   PB       Taqman           183    182       32      397    150     117   24       291    0.28   0.860   10
  Tanuma       2010   OSCC         Japan       Asian       HB       PCR-SSCP         69     53        28      150    42      48    10       100    0.34   0.487   7
  Batschauer   2011   Breast       Brazil      Caucasian   PB       PCR-RFLP         39     26        3       68     47      35    3        85     0.24   0.249   8
  Heinzle      2012   CRC          Austria     Caucasian   PB       Taqman           190    148       25      363    802     723   135      1660   0.30   0.114   14
  Yang         2012   HCC          China       Asian       HB       Taqman           216    351       144     711    247     361   132      740    0.42   0.996   13
  Fang         2013   Lung         China       Asian       HB       Sequencing       193    331       105     629    163     391   175      729    0.51   0.049   11
  Shen         2013   Gastric      China       Asian       PB       Sequencing       118    124       62      304    132     188   72       392    0.42   0.724   12
  Gao          2014   NHL          China       Asian       NA       PCR-RFLP         117    189       115     421    171     240   75       486    0.40   0.541   8
  Jiang        2015   Breast       China       Asian       NA       SNaPshot         205    404       138     747    270     348   98       716    0.38   0.398   11
  Sheu         2015   HCC          China       Asian       HB       Taqman           82     150       57      289    159     314   122      595    0.47   0.146   10

Abbreviations: MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium, CRC, colorectal cancer; HNSCC, head and neck squamous cell carcinoma; HCC, hepatocellular carcinoma; OSCC, oral squamous cell carcinoma; NHL, non-Hodgkin lymphoma; PB, population based; HB, hospital based; PCR-RFLP, polymorphism chain reaction-restriction fragment length polymorphism; PCR-SSCP, polymorphism chain reaction-single-stranded conformation polymorphism.

^a^ data was provided for AG/AA.

Association between *FGFR4* rs351855 G\>A polymorphism and cancer risk {#s2_2}
----------------------------------------------------------------------

The main findings of the meta-analysis are shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. Overall, the *FGFR4* rs351855 G\>A polymorphism was associated with increased cancer risk under the recessive model (OR=1.19, 95% CI=1.01-1.41). The association appeared to be negative under the homozygous (OR=1.19, 95% CI=0.98-1.44), heterozygous (OR=1.00, 95% CI=0.91-1.10), dominant (1.02, 95% CI=0.91-1.13), and allele contrast models (OR=1.07, 95% CI=0.98-1.16). Our data suggest that individuals with AA genotype of the *FGFR4* rs351855 G\>A polymorphism are at significantly increased cancer risk compared with AG and GG genotypes.

###### Meta-analysis of the association between *FGFR4* rs351855 G\>A polymorphism and cancer risk

  Variables           No. of studies   Homozygous             Heterozygous   Recessive              Dominant   Allele                                                                                   
  ------------------- ---------------- ---------------------- -------------- ---------------------- ---------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  All ^a^             27               1.19 (0.98-1.44)       \<0.001        1.00 (0.91-1.10)       0.012      **1.19 (1.01-1.41)**   \<0.001   1.02 (0.91-1.13)       \<0.001   1.07 (0.98-1.16)       \<0.001
  Cancer type                                                                                                                                                                                           
   Breast             6                **1.73 (1.35-2.20)**   0.960          1.17 (0.95-1.45)       0.186      **1.46 (1.17-1.83)**   0.986     **1.25 (1.02-1.52)**   0.197     **1.26 (1.14-1.41)**   0.622
   CRC                3                0.84 (0.59-1.19)       0.701          0.87 (0.72-1.06)       0.964      0.89 (0.63-1.26)       0.718     0.87 (0.72-1.04)       0.895     0.90 (0.78-1.04)       0.773
   Others             7                1.25 (0.85-1.84)       0.017          0.96 (0.81-1.14)       0.290      1.30 (0.92-1.85)       0.019     0.96 (0.77-1.18)       0.040     1.09 (0.92-1.30)       0.022
   Prostate           6                1.60 (0.99-2.61)       0.020          **1.16 (1.02-1.32)**   0.714      1.56 (0.92-2.65)       0.004     **1.20 (1.06-1.35)**   0.892     **1.22 (1.06-1.41)**   0.183
   Lung               2                **0.58 (0.40-0.83)**   0.231          **0.75 (0.61-0.91)**   0.596      **0.67 (0.53-0.85)**   0.388     **0.70 (0.58-0.85)**   0.332     **0.76 (0.67-0.86)**   0.358
   HCC                3                1.08 (0.84-1.38)       0.341          0.93 (0.68-1.28)       0.127      1.09 (0.89-1.33)       0.656     0.96 (0.73-1.28)       0.139     1.02 (0.88-1.19)       0.241
  Ethnicity                                                                                                                                                                                             
   Caucasians         14               1.05 (0.88-1.25)       0.349          1.04 (0.95-1.13)       0.497      1.02 (0.88-1.19)       0.448     1.00 (0.89-1.12)       0.116     1.03 (0.95-1.12)       0.192
   Asians             11               1.25 (0.90-1.73)       \<0.001        0.96 (0.80-1.16)       0.001      1.28 (0.99-1.66)       \<0.001   1.03 (0.84-1.26)       \<0.001   1.09 (0.93-1.28)       \<0.001
   African            2                2.17 (0.20-23.14)      0.169          1.05 (0.61-1.80)       0.322      2.21 (0.18-26.83)      0.019     1.11 (0.66-1.86)       0.617     1.15 (0.73-1.82)       0.948
  Source of control                                                                                                                                                                                     
   PB                 14               1.07 (0.90-1.27)       0.365          1.00 (0.88-1.13)       0.169      1.07 (0.92-1.25)       0.409     0.99 (0.87-1.12)       0.082     1.04 (0.96-1.12)       0.343
   ND                 3                **1.83 (1.30-2.56)**   0.175          **1.30 (1.03-1.64)**   0.218      **1.54 (1.08-2.22)**   0.088     **1.44 (1.19-1.76)**   0.283     1.34 (1.14-1.58)       0.170
   HB                 10               1.08 (0.77-1.51)       \<0.001        0.92 (0.81-1.05)       0.237      1.13 (0.84-1.50)       \<0.001   0.96 (0.81-1.13)       0.018     1.02 (0.87-1.18)       \<0.001

Abbreviations: Het, heterogeneity; CRC, colorectal cancer; HCC, hepatocellular carcinoma; HB, Hospital based; PB, Population based; ND, not determined.

![Forest plot of the association between the *FGFR4* rs351855 G\>A polymorphism and cancer risk under the recessive model](oncotarget-08-25300-g002){#F2}

Analysis stratified by cancer type indicated that *FGFR4* rs351855 \[A\] carriers have modestly increased risk of developing breast cancer (homozygous: OR=1.73, 95% CI=1.35-2.20; recessive: OR=1.46; 95%CI=1.17-1.83; dominant: OR=1.25, 95% CI=1.02-1.52; allele contrast: OR=1.26; 95% CI=1.14-1.41), and prostate cancer (heterozygous: OR=1.16, 95% CI=1.02-1.32; dominant: OR=1.20, 95% CI=1.06-1.35; allele contrast: OR=1.22, 95% CI=1.06-1.41). Conversely, a modest reduction in cancer risk was found for lung cancer (homozygous: OR=0.58, 95% CI=0.40-0.83; heterozygous: OR=0.75, 95% CI=0.61-0.91, recessive: OR=0.67, 95% CI=0.53-0.85; dominant: OR=0.70, 95% CI=0.58-0.85; allele contrast: OR=0.76, 95% CI=0.67-0.86). When stratified analysis was performed by ethnicity, no association between ethnicity and cancer risk was observed among Caucasians, Asians, and Africans. Stratified analysis by source of control revealed significant association in ND subgroup (homozygous: OR=1.83, 95% CI=1.30-2.56); heterozygous: OR=1.30, 95% CI=1.03-1.64, recessive: OR=1.54, 95% CI=1.08-2.22; dominant: OR=1.44, 95% CI=1.19-1.76), rather than in PB and HB subgroups.

A significant heterogeneity existed in the overall pooled analysis for the association of interest under all genetic models, as indicated by the *P* values of heterogeneity test (*P*^het^) in the Table [2](#T2){ref-type="table"}. Moreover, in the analyses stratified by cancer type, ethnicity, and source of control, significant heterogeneity was detected in prostate cancer, Asians, and in HB studies, respectively. Heterogeneity indicates diversity, which may result from differences in subjects, genotyping method, study design, sample size, ethnicity, and many other factors varying across studies. Therefore, the Mantel--Haenszel random effects model was used to decrease the effect of heterogeneity in these cases.

We assessed validity of the results by sensitivity analyses and examination of potential publication bias. Sensitivity analysis revealed that no individual study substantially altered the pooled results, showing the stability of the present meta-analysis ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). The meta-analysis was free of publication bias, as indicated by symmetrical funnel plots (Figure [3](#F3){ref-type="fig"}), and by the Egger\'s linear regression test (homozygous: *P*=0.461; heterozygous: *P*=0.085; recessive: *P*=0.229; dominant: *P*=0.27; allele contrast: *P*=0.938).
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DISCUSSION {#s3}
==========

The current meta-analysis demonstrates that the *FGFR* rs351855 G\>A polymorphism is associated with an increased cancer risk. Consistent with our study, a previous meta-analysis in 2010, which included 12 studies with 4,892 cases and 3,663 controls, suggested that the *FGFR* rs351855 G\>A polymorphism conferred increased genetic susceptibility to cancer \[[@R40]\]. The same meta-analysis also showed that the rs351855 G\>A polymorphism significantly elevated the risk of prostate cancer and breast cancer \[[@R40]\]. However, in the analysis stratified by cancer type, only three studies for breast cancer were included, and no study for lung cancer was reported \[[@R40]\]. Since 2010, new studies have emerged. The current meta-analysis of 27 studies comprising 8,682 cases and 9,731 controls, confirmed the increased cancer risk of the rs351855 G\>A polymorphism with increased statistical power. Moreover, our results indicate that the *FGFR4* rs351855 G\>A polymorphism increases the risk of prostate and breast cancer, but decreases the risk of lung cancer. The reasons why the *FGFR4* rs351855 G\>A polymorphism has opposite effects on different types of cancer are unclear, suggesting that other genetic and environmental factors might be involved, or that this polymorphism modifies cancer susceptibility in a tissue-specific manner. Alternatively, the association found with lung cancer might not be noteworthy, since only two studies were involved. Other two meta-analyses were performed regarding the *FGFR* rs351855 G\>A polymorphism \[[@R41], [@R42]\]. However, one study focused on the association between the polymorphism and prognosis (nodal status and overall survival) \[[@R41]\], and the other analysis only included studies on prostate cancer \[[@R42]\].

Interestingly, the *FGFR* rs351855 G\>A polymorphism genotypes are distributed differently among different ethnic groups \[[@R23], [@R40]\]. The current meta-analysis confirmed that the *FGFR* Arg^388^ allele is the most prevalent in Asians (40.1%), and then Caucasians (30.4%), and Africans (11.7%). However, analysis stratified by ethnicity failed to find any ethnic-specific association between the *FGFR* rs351855 G\>A polymorphism and cancer risk. That is inconsistent with the previous meta-analysis study \[[@R40]\], which reported a significant association in Asians, with almost half the sample size (11 studies vs. 6 studies).

The biological effect of the *FGFR4* Arg388 expression remains unclear. However, several lines of evidence indicate the implication of the rs351855 G\>A polymorphism in carcinogenesis. *In vitro* experiments with triple negative breast cancer cells (MDA-MB-231) demonstrated that cells expressing the *FGFR4* Arg388 variant have increased motility compared with cells expressing the *FGFR4* wide-type counterpart (Gly388) \[[@R18]\]. Wang et al. reported that compared to Gly388 cDNAs, transfection of *FGFR-4* Arg388 cDNAs promoted migration and invasion of PNT1A cells (prostatic epithelial cell line) \[[@R23]\].

However, no correlation has been established yet between the *FGFR4* rs351855 G\>A genotype and FGFR4 protein levels. A previous study did not detect any correlation between the *FGFR4* rs351855 G\>A genotype and FGFR4 protein expression among 104 HNSCC patients \[[@R43]\]. In addition, the Gly388Arg polymorphism did not alter FGFR4 protein expression in normal lung tissue \[[@R28]\]. FGFR4 serves as a receptor tyrosine kinase. However, the rs351855 G\>A polymorphism did not alter the tyrosine kinase activity of FGFR4 in breast cancer \[[@R18]\] and prostate cancer cells \[[@R23]\]. Therefore, the SNP may increase cancer risk through other mechanisms, including altering FGFR4′s ligand affinity, degradation, or its capacity to interact with downstream effectors. In this regard, Tateno et al. found that the *FGFR4* polymorphism contributes to pituitary tumorigenesis through increasing phosphorylation of the mitochondrial STAT, resulting in increased cell growth \[[@R44]\]. Ulaganathan and Ullrich have recently reported that replacement of the glycine residue with a charged arginine residue at codon 388 causes changes in the transmembrane region, which consequently exposes a membrane-proximal cytoplasmic STAT3 binding site Y390-(P)XXQ393 \[[@R45]\]. Such *de novo* exposure of the STAT3 binding site facilitates STAT3 tyrosine phosphorylation, thereby stimulating cell proliferation \[[@R45]\]. Collectively, the *FGFR4* rs351855 G\>A polymorphism may promote tumorigenesis by enhancing cell migration, invasion, and proliferation. More studies are needed to validate the association and investigate the underlying mechanisms. This SNP may hold a promise as a potential chemotherapeutic target and a biomarker to screen high-risk individuals.

There were some limitations in our meta-analysis study. First, the moderate sample size might have reduced the statistical power, especially in the stratified analyses. Second, because of the unavailability of demographic and environmental information, confounding factors could not be adjusted for, including age, sex, smoking, and drinking. Since the strength of the association was measured by crude ORs, our results might be open to confounding bias. Third, publication bias may be inevitable since we were only able to acquire data from unpublished articles. Finally, the meta-analysis was associated with a significant heterogeneity, which might weaken reliability of the meta-analysis.

In conclusion, our study demonstrates the association between the *FGFR4* rs351855 G\>A polymorphism and overall cancer risk. In terms of cancer type, the *FGFR4* rs351855 G\>A polymorphism was found to modify susceptibility to breast, prostate, and lung cancer.

MATERIALS AND METHODS {#s4}
=====================

The meta-analysis was performed according to the latest meta-analysis guidelines (PRISMA) \[[@R46]\].

Data sources {#s4_1}
------------

We retrieved all the published studies relating the *FGFR4* rs351855 G\>A polymorphism and cancer risk by searching PubMed and EMBASE databases. The combination of search terms were as follows: "FGFR4 or fibroblast growth factor receptor 4", "rs351855 or Gly388Arg", "polymorphism or variation or variant", and "cancer or carcinoma or tumor". The latest search was carried out in October 2016. We also examined the reference lists of the relevant original publications and review articles as well as previously published meta-analyses to maximize the coverage of the current meta-analysis. No language restriction was applied.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Inclusion and exclusion criteria were predetermined as described previously \[[@R47]--[@R49]\]. To be included, studies had to: (i) be case-control or cohort studies, (ii) assess the association between the *FGFR4* rs351855 G\>A polymorphism and cancer risk, and (iii) provide adequate data for calculating odd ratios (ORs) and 95% confidence intervals (CIs). We discarded case reports, case only studies, review articles, and conference abstracts. Additionally, we excluded studies that departed from Hardy--Weinberg equilibrium (HWE) (*P* ~HWE~ \< 0.05) in controls, if there was no extra evidence from another *FGFR4* polymorphism satisfying HWE. When duplicate studies occurred, only the most recent or the largest study was included.

Data extraction {#s4_3}
---------------

Two investigators (Fen Feng and Jianqun Ma) obtained data from individual studies independently following a standardized data extraction form. Data were extracted by name of the first author, year of publication, country where the study was conducted, ethnicity, genotype counts of cases and controls for the *FGFR4* rs351855 G\>A polymorphism, source of controls (controls were chosen from the general population or a hospital), genotype method, and the *P*-value of HWE in controls. The subgroups were defined by cancer type, ethnicity, and source of control \[hospital-based (HB) and population-based (PB)\]. Publications containing different ethnicities, cancer types or different regions, were separated into different categories. The extracted information was imported into excel worksheets and examined for inconsistency. Conflicts were resolved by discussion between the two authors and a consensus would be reached ultimately.

Quality assessment {#s4_4}
------------------

The quality of studies was scored based on the following criteria: representativeness of case, representativeness of control, ascertainment of cancer case, control selection, genotyping examination, HWE, and total sample size as described in previous study \[[@R50]\]. The final quality score ranged from 0 (lowest) to 15 (highest). A score of 9 was used as a cutoff value (high quality: \> 9; low quality: ≤ 9).

Statistical analysis {#s4_5}
--------------------

A goodness-of-fit chi-square test was run to check departure from HWE for the *FGFR4* rs351855 G\>A polymorphism in controls. The common measure of association across studies, the OR with 95% CI, was applied to the meta-analysis. The strength of the association between the *FGFR4* rs351855 G\>A polymorphism and cancer risk was determined under the four genetic models (homozygous: AA vs. GG; heterozygous: AG vs. GG; recessive: AA vs. AG/GG; dominant: AG/AA vs. GG) and allele contrast was performed (A vs. G). We performed standard chi-square tests and the I^2^ statistic to quantify between-study heterogeneity \[[@R51]\]. If significance between-study heterogeneity was detected, summary ORs (95% Cls) were computed using a Mantel--Haenszel random effects model to decrease the effect of heterogeneity. If not, fixed effects model would take effect. Cancer type, ethnicity, and source of control were specified as study level characteristics for evaluating the source of heterogeneity using stratified analysis \[[@R52]\]. In order to explore the impact of each individual study on pooled risk estimates, we also carried out sensitivity analyses, which were fulfilled by leaving out one study at a time and recalculating ORs for the remaining studies. Publication bias was assessed through Begg\'s funnel plots \[[@R53]\] and Egger\'s linear regression test \[[@R54]\]. All analyses were conducted using STATA version 12 (Stata Corp, College Station, TX). All statistical analyses were two-sided, and a value of *P* \<0.05 was considered significant.

SUPPLEMENTARY FIGURE {#s5}
====================

The study was supported by a grant from the Natural Science Foundation of Heilongjiang Province, China (No. H2015049), the scientific cultivation and innovation fund of JiNan University (21614305), and by Natural Science Foundation of China (81402143).

**CONFLICTS OF INTEREST**

The authors declare that no conflicts of interest exist.
